DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that President and Chief Executive Officer Richard Gabriel will present an overview of the Company to investors at the ValueRich Small-Cap Financial Expo on Thursday, June 21 at 11:40 a.m. Eastern time at the W New York Hotel, 541 Lexington Ave., in New York City.

The twenty-minute presentation will be webcast live at: http://www.visualwebcaster.com/ValueRich/40379/event.html, where it will be archived for one year after the event. The Company is also sponsoring a table at the Expo at which senior management will be available throughout the day.

For more information about attending the ValueRich Small-Cap Financial Expo, please visit: http://www.ivaluerich.com/expo.php.

About ValueRich, Inc.

ValueRich, Inc. operates various online and offline media-based properties for corporate and financial professionals, including ValueRich magazine (http://ivaluerich.com/magazine.php); the large-scale ValueRich Small-Cap Financial Expos (http://ivaluerich.com/expo.php) and the industry-wide online financial community iValueRich.com (http://www.ivaluerich.com/). The Company's corporate mission is to create the world's largest and most active community of financial professionals and small-cap public company executives through its integrated portfolio of products and services.

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.